Neuroimmunology Drug Development - Thematic Research

Neuroimmunology Drug Development - Thematic Research

Summary

This report provides an overview of neuroimmunology drug development within eight key indications across eight pharmaceutical markets.

The neuroimmune system is complex and a critical component in regulating nervous system health and disease. GlobalData defines a neuroimmunology drug as an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Various neuroimmunology therapeutic strategies are being studied and used in order to help treat neurological diseases, including drugs that target different types of cytokines, drugs that bind selectively to receptors, and drugs that affect the migration of immune cells. Different types of molecules constituting neuroimmunology drugs are considered in this report including monoclonal antibodies, small molecules, recombinant products, and vaccines. This report focuses on neuroimmunology drug development within eight key indications (MS, NMOSD, GBS, CIDP, MG, AD/MCI, PD, and ALS) across eight major pharmaceutical markets (8MM: the US, 4EU, the UK, Japan, and China).

Key Highlights

• Report deliverable include a PowerPoint report.
• Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for MS (23 drugs), followed by three each for NMOSD and AD, and two for MG. Most marketed neuroimmunology products are small molecules (12 drugs), followed by mAbs (nine drugs) and recombinant proteins (seven drugs).
• According to GlobalData’s Drugs Database, there are currently almost 220 neuroimmunology drugs in Phase I, II, III, and later stages of development in the 8MM. The highest number of drugs are in development for AD (75 drugs), followed by amyotrophic lateral sclerosis (ALS) (39 drugs), PD (35 drugs), MS (26 drugs), and relapsing-remitting MS (RRMS) (26 drugs).
• The top 20 neuroimmunology products were worth $20.1 billion in 2020 and are expected to be worth $26.6 billion by 2025. Growth is driven primarily by the continued uptake of Ocrevus in MS and new launches across several indications. Extensive deal-making is occurring within the neuroimmunology drug space, with the top-valued deal being the acquisition of Alexion Pharmaceuticals by AstraZeneca, announced in December 2020.
• Of the ten key players involved in the neuroimmunology market, Roche, Biogen, AstraZeneca, Johnson & Johnson (J&J), Novartis, Sanofi, and UCB are all involved in marketing or developing neuroimmunology products across multiple neurological indications. The remaining three players are instead focused on neuroimmunological products in just one indication each-Merck KGaA in MS and Eisai and Lilly in AD.

• Overview of the neuroimmune system and its role in the pathology of eight key neurological diseases
• Overview of key trends in the neuroimmunology drug development space
• Evaluation of marketed and pipeline neuroimmunology drugs for the treatment of eight key neurological diseases, highlighting key mechanisms of action
• Evaluation of clinical trials for marketed and pipeline neuroimmunology drugs
• Market analysis of key neuroimmunology products in 2020 and 2025 plus an overview of key deals in the neuroimmunology space
• Overview of opportunities and unmet needs in the neuroimmunology space
• Analysis of companies developing neuroimmunology drugs, with a focus on major players

• Develop and design your in-licensing and out-licensing strategies through a review of neuroimmunology pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global neuroimmunology drug market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuroimmunology market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.